About This Desk

What this desk is

Peptide Consultation is an independent research digest covering three peptides that sit in three unrelated corners of the literature: semaglutide, tesamorelin and PT-141 (bremelanotide). It has one job — to report what the published, peer-reviewed record establishes about each of them, and to be equally explicit about what that record leaves unresolved.

It is not a clinic and not a practice. It provides no consultation, arranges none, and has no affiliation with any prescriber, pharmacy, laboratory or vendor. Nothing on it is for sale and no source of material is recommended. The name is a description of a subject — the questions that belong in a clinical conversation rather than on a web page — not an offer of a service.

The editorial position is deliberately narrow, and narrowness is the point. A reference desk that stays inside the published record is more useful than one that extrapolates past it, because the extrapolation is exactly where a reader would be misled.

How the sources are handled

Every page here is built from a fixed, numbered reference list, reproduced in full on the references page.

Quantities carry citations. Percentages, participant counts, durations, effect sizes, confidence intervals and half-lives all trace to a numbered entry. Where a figure is discussed in the wider field but not supported by a listed source, this desk says so instead of quoting it — a slightly awkward sentence being preferable to a number with nothing behind it.

Anecdote is separated from evidence and labelled. Community reports appear on the compound pages under an explicit statement that they are anecdotal, not clinical evidence. They are never given dose figures and never presented as findings.

Negative and inconvenient results stay in. An animal study that failed to confirm an expected mechanism ^[11] is reported alongside the human imaging study that supports a central effect ^[12]. A head-to-head trial in which the compound on this desk came second is reported with its numbers intact ^[1]. A safety signal described as unconfirmed is described as unconfirmed rather than as absent ^[5].

No dose is recommended. Doses appear only as descriptions of what a cited trial or an approved label specified, which is a fact about that study or label.

Where the reading stops

Three kinds of question fall outside this desk entirely, and naming them is more honest than implying a general competence.

The first is individual applicability. Trials describe groups; whether a group result transfers to a particular person depends on that person's history, medications, comorbidities and priorities, none of which a published paper contains.

The second is anything requiring examination, monitoring or a prescription. The labels cited on these pages carry contraindications — uncontrolled hypertension and cardiovascular disease for bremelanotide ^[15], active malignancy for tesamorelin, pregnancy for semaglutide — that only a clinician with a full record can apply.

The third is unverified material. Every result reported here was produced with a characterised pharmaceutical. Material sold outside that framework has no verified identity, purity or concentration, and no finding on this site describes it.

What remains after those exclusions is a reasonable amount: a clear account of what has been measured, in whom, for how long, and with what caveats. That is what a reference desk can honestly offer.